ALX Oncology Holdings Inc.

NasdaqGS:ALXO Stock Report

Market Cap: US$96.5m

ALX Oncology Holdings Management

Management criteria checks 1/4

ALX Oncology Holdings' CEO is Jason Lettmann, appointed in Sep 2023, has a tenure of 1.25 years. total yearly compensation is $5.32M, comprised of 4.1% salary and 95.9% bonuses, including company stock and options. directly owns 0.22% of the company’s shares, worth $213.98K. The average tenure of the management team and the board of directors is 1.3 years and 4.4 years respectively.

Key information

Jason Lettmann

Chief executive officer

US$5.3m

Total compensation

CEO salary percentage4.1%
CEO tenure1.3yrs
CEO ownership0.2%
Management average tenure1.3yrs
Board average tenure4.4yrs

Recent management updates

Recent updates

ALX Oncology's Evorpacept Gains Momentum With FDA Fast Track Designations

Sep 12

ALX Oncology: Finally Reaching A Reasonable Buy-In Valuation

Jun 27

ALX Oncology: Trying To Justify The Hype

Apr 18

Is ALX Oncology Holdings (NASDAQ:ALXO) Using Debt In A Risky Way?

Mar 12
Is ALX Oncology Holdings (NASDAQ:ALXO) Using Debt In A Risky Way?

ALX Oncology GAAP EPS of -$0.81 misses by $0.18

Aug 08

ALX Oncology stock rises on FDA fast track status for evorpacept to treat head/neck cancer

Aug 01

ALX Oncology stock rises 14% on evorpacept's FDA orphan drug status for blood cancer

Jun 29

ALX Oncology Is Turning Into An Also-Ran In Anti-CD47

Feb 15

ALX Oncology Stock: Attractive After Recent Data And Slump In Price

Nov 30

ALX Oncology Is The Next CD47 Biotech To Watch After Recent Acquisitions In This Space

Sep 08

Here's Why We're Not Too Worried About ALX Oncology Holdings' (NASDAQ:ALXO) Cash Burn Situation

Jul 08
Here's Why We're Not Too Worried About ALX Oncology Holdings' (NASDAQ:ALXO) Cash Burn Situation

Dosing underway in ALX Oncology's ALX148 combo study in head and neck cancer

May 10

We're Not Very Worried About ALX Oncology Holdings' (NASDAQ:ALXO) Cash Burn Rate

Mar 25
We're Not Very Worried About ALX Oncology Holdings' (NASDAQ:ALXO) Cash Burn Rate

Here's What ALX Oncology Holdings Inc.'s (NASDAQ:ALXO) Shareholder Ownership Structure Looks Like

Feb 01
Here's What ALX Oncology Holdings Inc.'s (NASDAQ:ALXO) Shareholder Ownership Structure Looks Like

ALX Oncology: All Their Eggs In The Proverbial Basket

Jan 07

CEO Compensation Analysis

How has Jason Lettmann's remuneration changed compared to ALX Oncology Holdings's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$151m

Jun 30 2024n/an/a

-US$171m

Mar 31 2024n/an/a

-US$166m

Dec 31 2023US$5mUS$217k

-US$161m

Sep 30 2023n/an/a

-US$146m

Jun 30 2023n/an/a

-US$130m

Mar 31 2023n/an/a

-US$129m

Dec 31 2022US$116kn/a

-US$123m

Sep 30 2022n/an/a

-US$121m

Jun 30 2022n/an/a

-US$110m

Mar 31 2022n/an/a

-US$94m

Dec 31 2021US$537kn/a

-US$83m

Sep 30 2021n/an/a

-US$74m

Jun 30 2021n/an/a

-US$60m

Mar 31 2021n/an/a

-US$58m

Dec 31 2020US$352kn/a

-US$51m

Compensation vs Market: Jason's total compensation ($USD5.32M) is above average for companies of similar size in the US market ($USD650.00K).

Compensation vs Earnings: Jason's compensation has increased whilst the company is unprofitable.

CEO

Jason Lettmann (47 yo)

1.3yrs

Tenure

US$5,320,096

Compensation

Mr. Jason W. Lettmann had been an Independent Director of ALX Oncology Holdings Inc. since April 2020 until September 6, 2023 and previously served as a Director from March 2015 to May 2017 also serves as...

Leadership Team

NamePositionTenureCompensationOwnership
Jason Lettmann
CEO & Director1.3yrsUS$5.32m0.22%
$ 214.0k
Jaume Pons
Founder9.7yrsUS$2.75m0.88%
$ 844.6k
Shelly Pinto
Interim Chief Financial Officerno dataUS$7.23m0.066%
$ 63.5k
Michael Chang
Vice President of Operationsno datano datano data
Caitlyn Doherty
Manager of Investor Relations & Corporate Communicationsno datano datano data
Christopher Byrd
General Counsel2.6yrsno datano data
Athanasios Tsiatis
Senior Vice President of Clinical Development3.1yrsno datano data
Lin Yeong-Liang
Senior Vice President of Drug Safety & Pharmacovigilance2.5yrsno datano data
Lisa Sauer
Senior Vice President of Regulatory Affairs & Quality Assurance1.3yrsno datano data
Sue Naim
Senior Vice President of Clinical Operationsless than a yearno datano data
Allison Dillon
Chief Business Officerless than a yearno datano data
Venita De Almeida
VP & Head of Research Program Developmentless than a yearno datano data

1.3yrs

Average Tenure

48yo

Average Age

Experienced Management: ALXO's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Jason Lettmann
CEO & Director4.7yrsUS$5.32m0.22%
$ 214.0k
Jaume Pons
Founder9.7yrsUS$2.75m0.88%
$ 844.6k
Corey Goodman
Chairman9.8yrsUS$206.61k0.32%
$ 306.3k
Keith Flaherty
Chair of the Scientific Advisory Board4.2yrsno datano data
Scott Garland
Independent Director2.1yrsUS$105.66k0%
$ 0
Charles Baum
Member of the Scientific Advisory Board4.2yrsno datano data
Rekha Hemrajani
Independent Director4.7yrsUS$181.02k0.063%
$ 60.4k
Kipp Weiskopf
Member of the Scientific Advisory Board4.2yrsno datano data

4.4yrs

Average Tenure

55yo

Average Age

Experienced Board: ALXO's board of directors are considered experienced (4.4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 02:09
End of Day Share Price 2024/12/26 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

ALX Oncology Holdings Inc. is covered by 7 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Alethia YoungCantor Fitzgerald & Co.
Li Wang WatsekCantor Fitzgerald & Co.
Martin AusterCredit Suisse